Group 1 - The core point of the article is that Fosen Pharmaceutical (01652) announced that one of its products, Metformin and Empagliflozin Tablets (containing 500mg Metformin Hydrochloride and 5mg Empagliflozin), is expected to win a bid in China's 11th national centralized drug procurement tender scheduled for October 27, 2025 [1] Group 2 - The product involved in the tender is a combination of Metformin and Empagliflozin, which are commonly used in the treatment of type 2 diabetes [1] - Winning the bid could enhance the company's market presence and sales potential in the competitive pharmaceutical landscape in China [1] - The announcement reflects the company's ongoing efforts to expand its product portfolio and participate in national procurement initiatives [1]
福森药业(01652)：二甲双胍恩格列净片(I)拟中标中国第11批全国药品集中采购招标